AAN Annual Meeting - American Academy of Neurology Annual Meeting

In this debut episode Erica Marini and her colleagues discuss the critical role pharmacists play in complex neurologic care and the latest emerging therapies and research presented at the AAN 2026 Annual Meeting.

Rapport Therapeutics' RAP-219 achieved seizure freedom in 24% of patients with drug-resistant focal epilepsy over 8 weeks in a phase 2 trial.

A cognitive neurologist outlines the current Alzheimer disease treatment landscape.

AI is delivering immediate clinical value in neurology—from ambient scribes and clinical decision support to trial recruitment and medical education.

A Harvard population health researcher presents findings linking adolescent food insecurity to a cluster of brain health risk factors.

Ecopipam reduces Tourette tic relapse risk by approximately 50% with durable control and no movement-related adverse effects.

Phase 3 data show quarterly cemdisiran injections improve gMG symptoms, either and matches or outperforms all study end points compared to combination therapy.

Cannabidiol may have broader applicability across genetic developmental and epileptic encephalopathies (DEEs).

Bocunebart, a novel anti-PACAP antibody, targets a distinct neurological pathway from existing CGRP therapies.

Phase 3 METEOROID shows IL-6 blocker satralizumab cuts MOGAD relapses 68%, with rapid onset and placebo-like safety.

Cemdisiran’s RNA-targeting mechanism is a compelling new option in the generalized myasthenia gravis treatment landscape.

The research highlights the influence of hormonal changes on treatment selection and the need for more tailored, life stage–specific care.

The data, which were presented at the AAN 2026 Annual Meeting, support the agents’ neurological safety, but longer follow-ups and dedicated outcome trials are needed to confirm these findings.

Phase 3 SYMPHONY clinical trial data show reboxetine eases narcolepsy type 1 symptoms, improving functional impairment due to excessive daytime sleepiness (EDS) as well as mood symptoms.

Biological sex and societal gender factors independently—and differently—influence TBI mortality, discharge destination, and long-term cognitive recovery.

Despite the availability of 4 FDA-approved biologics, the majority of NMOSD patients remain on off-label rituximab.

The menopausal transition alters brain circuitry and estrogen signaling in ways that may elevate risk for Alzheimer disease.

Sex and gender differences remain critically underrepresented in traumatic brain injury clinical guidelines.

Integrated health system specialty pharmacies can improve patient care for non–multiple sclerosis neurologic conditions.

Logan Schneider, MD, highlights the importance of integrating patient-reported outcomes into clinical trials to better capture the full therapeutic impact of low-sodium oxybate (Xywav) beyond traditional sleep metrics.

Paula E. Voinescu, PhD, MD, emphasized the need for additional research in this area, noting it is both “surprising and upsetting.”

Logan Schneider, MD, explains the latest findings on narcolepsy and idiopathic hypersomnia treatments, highlighting patient experiences and sleep architecture improvements.

Philip Kuball, MD, neurology resident at NYU Langone Health, highlights the integral role of pharmacists in monitoring patient eligibility, managing dosing schedules, and ensuring safe medication interactions for lecanemab treatment in Alzheimer disease.

Lauren B. Krupp, MD, FAAN, provides comprehensive guidance on treating pediatric multiple sclerosis, emphasizing early intervention, high-efficacy therapies, and holistic family support.

Nipocalimab with standard of care helped patients with generalized myasthenia gravis (gMG) maintain improvements in daily living and quantitative scores compared with placebo.

The future holds the promise of earlier diagnosis, more targeted therapies, and personalized neurological care, said speaker William D. Freeman, MD, FAAN.

Huntington disease (HD) has no curative treatments, therefore, there is a great need for therapies that can reduce or slow the progression of symptoms.

Nilufer Ertekin-Taner contrasts current one-size-fits-all Alzheimer disease treatments with the promise of precision medicine and emphasizes the vital role of collaborative, multidisciplinary care.

The HERCULES trial demonstrates tolebrutinib's potential to slow disability progression in non-relapsing secondary progressive multiple sclerosis, offering a new treatment option for patients with limited therapeutic choices.